Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

MR-Guided Focused Ultrasound in the Treatment of Focal Epilepsy (EP001)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02804230
Recruitment Status : Recruiting
First Posted : June 17, 2016
Last Update Posted : October 5, 2021
Sponsor:
Information provided by (Responsible Party):
InSightec

Brief Summary:
The purpose of this study is to evaluate the feasibility, safety, and initial effectiveness of Exablate thermal ablation of a focal epileptic target area in the brain of patients suffering from medication-refractory epilepsy, using the Exablate transcranial system to produce multiple sonications targeted in the focus of interest. The investigators will establish the feasibility and collect data to establish the basic safety of this type of treatment as the basis for later studies that will evaluate its full clinical efficacy.

Condition or disease Intervention/treatment Phase
Epilepsy, Unspecified, Refractory (Medically) Device: MRgFUS Ablation of Epileptic Foci Not Applicable

Detailed Description:

The purpose of this study is to evaluate the feasibility, safety, and initial effectiveness of Exablate thermal ablation of a focal epileptic target area in the brain of patients suffering from medication-refractory epilepsy, using the Exablate transcranial system to produce multiple sonications targeted in the lesion of interest. The Investigators will establish the feasibility and collect data to establish the basic safety of this type of treatment as the basis for later studies that will evaluate its full clinical efficacy.

The hypotheses tested are that:

  1. MRgFUS treatment of focal epilepsy is feasible and safe, with a low risk of adverse effects as evaluated during the follow-up period.
  2. Exablate treatment of foci in patients with focal epilepsy reduces the seizure frequency.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 20 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Feasibility Study to Evaluate Safety and Initial Effectiveness of MR-Guided Focused Ultrasound Ablation Therapy in the Treatment of Focal Epilepsy
Study Start Date : June 2016
Estimated Primary Completion Date : June 2023
Estimated Study Completion Date : June 2024


Arm Intervention/treatment
Experimental: MRgFUS Ablation of Epileptic Foci
MR-Guided Focused Ultrasound
Device: MRgFUS Ablation of Epileptic Foci
MR-Guided Focused Ultrasound
Other Names:
  • MRgFUS
  • FUS
  • Focused Ultrasound
  • MR-Guided Focused Ultrasound




Primary Outcome Measures :
  1. Incidence and severity of device and procedure related complications [ Time Frame: At the time of ExAblate Transcranial procedure ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients who are able and willing to give consent and able to attend all study visits.
  • Seizure refractory to at least three standard antiepileptic medications at adequate doses, failed for lack of efficacy. This may include a rescue medication designated use as PRN.
  • A minimum of 3 seizures per month for 2 months by patient diary started at intake interview.
  • Subjects should have focal seizures with or without secondary generalization.
  • Subjects should have evidence suggesting the focus within the periventricular white matter, basal ganglia, thalamus, or hypothalamus has been previously determined as the source of seizures by standard clinical criteria including at least the description of seizures, physical examination, neuroimaging, and video EEG monitoring capturing at least one seizure.
  • Subjects must be taking 2 medications during the Baseline period and the dosage must be stable.
  • A diagnosis of intractable lesional epilepsy which may include: Hypothalamic hamartoma, Periventricular nodular hetereotopia, Dysembryoplastic neuroepithelial tumor (DNET), Cortical dysplasia, Tuberous sclerosis, or Focal cortical gliosis.

Exclusion Criteria:

  • Patients with unstable cardiac status that would increase anesthetic risk including: unstable angina pectoris on medication, documented myocardial infarction within six months of protocol entry, congestive heart failure requiring medication (other than diuretic), anti-arrhythmic drug use.
  • Patients exhibiting any behavior(s) consistent with ethanol or substance abuse as defined by the criteria outlined in the DSM-IV as manifested by one (or more) of the following occurring within a 12 month period:

    • Recurrent substance use resulting in a failure to fulfill major role obligations at work, school, or home (such as repeated absences or poor work performance related to substance use; substance-related absences, suspensions, or expulsions from school; or neglect of children or household,
    • Recurrent substance use in situations in which it is physically hazardous (such as driving an automobile or operating a machine when impaired by substance use),
    • Recurrent substance-related legal problems (such as arrests for substance related disorderly conduct),
    • Continued substance use despite having persistent or recurrent social or interpersonal problems caused or exacerbated by the effects of the substance (for example, arguments with spouse about consequences of intoxication and physical fights).
  • Severe hypertension (diastolic BP > 100 on medication) measured at intake interview or on Treatment Day.
  • Patients with standard contraindications for MR imaging such as non-MRI compatible implanted metallic devices including cardiac pacemakers, size limitations, etc.
  • Known intolerance or allergies to the MRI contrast agent (i.e. Gadavist) including advanced kidney disease.
  • Known or suspected sensitivity to perfluetren (Definity®).
  • Severely impaired renal function (estimated glomerular filtration rate < 45ml/min/1.73 m2) or receiving dialysis.
  • History of abnormal bleeding and/or coagulopathy.
  • Receiving anticoagulant (e.g. warfarin) or antiplatelet (e.g. aspirin) therapy within one week of focused ultrasound procedure or drugs known to increase risk of hemorrage (e.g. Avastin) within one month of focused ultrasound procedure; or, unable or unwilling to stop anticoagulant for the purposed of focused ultrasound procedure.
  • Active or suspected acute or chronic uncontrolled infection.
  • History of intracranial hemorrhage.
  • Cerebrovascular disease (multiple CVA or CVA within 6 months).
  • Individuals who are not able or willing to tolerate the required prolonged stationary supine position during treatment (can be up to 4 hrs of total table time).
  • Symptoms and signs of increased intracranial pressure (e.g. headache, nausea, vomiting, lethargy, and papilledema).
  • Are participating or have participated in another clinical trial in the last 30 days.
  • Presence of any other neurodegenerative disease.
  • Present of cognitive impairment severe enough to be unable to understand and consent for the study, or understand the procedures.
  • History of immunocompromise, including patient who is HIV positive.
  • Known life-threatening systemic disease.
  • Patient with current or a prior history of current suicidal ideation or previous suicide attempt within the past year.
  • Patients with risk factors for intraoperative or postoperative bleeding (platelet count less than 100,000 per cubic millimeter, PT > 14, PTT > 36 or INR > 1.3) or a documented coagulopathy.
  • Patients with malignant brain tumors.
  • Any illness that in the investigator's opinion precludes participation in this study.
  • Pregnancy or lactation.
  • Legal incapacity or limited legal capacity.
  • Patients with a known history of psychogenic non-epileptic spells in the last three years.
  • Patients with a vagal nerve stimulator, deep brain stimulator, other implanted electronic device, or prior radiofrequency lesion techniques.
  • Patient with cardiopulmonary or vascular illness that would complicate anesthesia.
  • Patients who are unwilling to undergo general anesthesia.
  • Patients with lesions in the brainstem or cerebellum.
  • Patients with symptomatic generalized epilepsy.
  • Patients with only simple partial seizures.
  • Patients who have had convulsive status epilepticus within 12 months prior to baseline.
  • Patients with a prior diagnosis of psychogenic/non-epileptic seizures within the last 5 years.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02804230


Contacts
Layout table for location contacts
Contact: Jill Christensen jillc@insightec.com

Locations
Layout table for location information
United States, California
Stanford University Medical Center Recruiting
Stanford, California, United States, 94305
Contact: Jordan Seliger    650-460-9260    jseliger@stanford.edu   
Principal Investigator: Robert Fisher, MD         
United States, Kansas
University of Kansas Medical Center Recruiting
Kansas City, Kansas, United States, 66160
Contact: Eric Penner       epenner@kumc.edu   
Principal Investigator: Michael Kinsman, MD         
United States, Minnesota
Mayo Clinic Recruiting
Rochester, Minnesota, United States, 55905
Contact: Matt Hoplin    507-422-2121    hoplin.matthew@mayo.edu   
Principal Investigator: Jamie Van Gompel, MD         
United States, Virginia
University of Virginia Recruiting
Charlottesville, Virginia, United States, 22908
Contact: Stacy Thompson    434-982-4315    SRC2H@hscmail.mcc.virginia.edu   
Principal Investigator: Nathan Fountain, MD         
Sponsors and Collaborators
InSightec
Investigators
Layout table for investigator information
Principal Investigator: Nathan Fountain, MD University of Virginia
Layout table for additonal information
Responsible Party: InSightec
ClinicalTrials.gov Identifier: NCT02804230    
Other Study ID Numbers: EP001
First Posted: June 17, 2016    Key Record Dates
Last Update Posted: October 5, 2021
Last Verified: October 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided
Additional relevant MeSH terms:
Layout table for MeSH terms
Epilepsy
Epilepsies, Partial
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases